Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Effect of anti-tuberculosis treatment on body composition during the intensive phase Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Influence of early diagnostics with Xpert MTB/RIF on MDR TB patients treatment efficacy Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016